Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)
Authors
Cathomas, RCrabb, S
Kenner, H
Mark, M
Rothermundt, C
Elliott, Tony
Winterhalder, R
Von Burg, P
Vilei, S
Hayoz, S
Rauch, D
Roggero, E
Stenner, F
Berthold, D
Erdmann, A
Fischer, N
Manetsch, G
Gillessen, S
Affiliation
Kantonsspital Graub¨unden, Medical Oncology, Chur, SwitzerlandIssue Date
2015